Microscale and Macroscale Brain Disruptions Are Associated in Schizophrenia
Reports new study in Biological Psychiatry
Reports new study in Biological Psychiatry
Philadelphia, PA, August 16, 2016
Brain abnormalities in schizophrenia have been identified at the microscale (alterations in synaptic connections between neurons) and the macroscale (altered connections between brain regions). Findings of these two levels of abnormalities have emerged separately, but a new study in Biological Psychiatryreports that the microscale and macroscale changes may go hand in hand.
“This study suggests that disturbances in connections between nerve cells in the brain emerge together in schizophrenia,” said John Krystal, Editor of Biological Psychiatry.
Research on the neurobiological origins of schizophrenia indicates a reduction in the density of neuronal spines, where neurons form connections with each other to communicate. In parallel, magnetic resonance imaging (MRI) studies have shown reductions in large-scale white matter, the pathways connecting different brain regions. But how changes in these two levels of connectivity relate in schizophrenia remained an open question.
“This is quite remarkable, as in the end they both describe the same system, namely our brain,” said first author Martijn van den Heuvel, from the University Medical Center Utrecht in The Netherlands. “So in my book, there has to be a link between these two scales of brain organization.”
In their goal to bridge microscale cellular findings with macroscale MRI findings, the authors first studied the micro-macro association in healthy people. They collated data from published studies on spine density and cross-analyzed it with imaging data of long-range white matter connections that they derived from the Human Connectome Project. They found an association between microscale spine density, which indicates neuronal complexity, and the complexity of macroscale connections in the cortex.
To determine how the microscale changes relate to macroscale changes in schizophrenia, the researchers then analyzed spine density changes in schizophrenia, collated from published studies, with data on changes in MRI connectivity. They found a strong overlap in those regions showing the largest effects in spine density reductions and regions showing the largest effects of macroscale connectivity. The results suggest a possible relationship between the often, but independently, reported micro- and macroscale abnormalities.
According to van den Heuvel, bridging neuronal and macroscale connectivity completes an important missing link in schizophrenia research, and provides the first steps in understanding how changes in neuronal properties are related to changes in white matter connectivity in schizophrenia.
“Our study shows that we should no longer interpret neuronal and macroscale findings independently from each other, but that they likely strongly influence each other and are perhaps related to a similar disease origin,” said van den Heuvel.
Krystal noted that the finding supports a view of the brain as a highly adaptive organism, where disturbances in some components of brain function result in coordinated effects on brain circuits.
“Understanding the cross-scale link brings us one step closer to understanding the etiology of the disorder,” said van den Heuvel, “and this hopefully brings us closer to finding new treatment strategies for this severe psychiatric disorder.”
Notes for editors
The article is "Associated Microscale Spine Density and Macroscale Connectivity Disruptions in Schizophrenia," by Martijn P. van den Heuvel, Lianne H. Scholtens, Marcel A. de Reus, and René S. Kahn (doi: 10.1016/j.biopsych.2015.10.005). It appears in Biological Psychiatry, volume 80, issue 4 (2016), published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 214 648 0880 or firstname.lastname@example.org. Journalists wishing to interview the authors may contact Martijn van den Heuvel at M.P.email@example.com.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 140 Psychiatry titles and 11th out of 256 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2015 Impact Factor score for Biological Psychiatry is 11.212.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Editorial Office, Biological Psychiatry
+1 214 648 0880